Proteolysis in human breast and colorectal cancer

British Journal of Cancer

Volumn 81, Issue 2, 1999, Pages 287-293

  Garbett, E A ^a   Reed, M W R ^b   Brown, N J ^b  

^a UNIVERSITY HOSPITAL OF NORTH TEES   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Breast cancer; Colorectal cancer; Matrix metalloproteinases (MMPS); Metastasis; Proteolysis

Indexed keywords

GELATINASE A; GELATINASE B; PLASMINOGEN ACTIVATOR; PROTEINASE; PROTEINASE INHIBITOR; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UROKINASE;

ARTICLE; BREAST CANCER; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; FLUORESCENCE; HUMAN; HUMAN TISSUE; HYDROLYSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN DEGRADATION; WESTERN BLOTTING; ZYMOGRAPHY;

BLOTTING, WESTERN; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; EXTRACELLULAR MATRIX; FLUORESCENCE; HUMANS; METALLOENDOPEPTIDASES; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR CELLS, CULTURED;

EID: 0032832820     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690689     Document Type: Article

References (37)

1. Baramova E and Fuidart JM (1995) Matrix metalloproteinase family. Cell Biol Int 19: 239-242
2. Barrett AJ (1995) Classification of peptidases. Methods Enzymol 244: 1-15
3. Bouchet C, Spyratos F, Martin PM, Hacene K, Gentile A and Oglobine J (1994) Prognostic value of urokinase type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 69: 398-405
4. Brown CJ, Rahman S, Morton AC, Beauchamp CL, Bramwell H and Buttle DJ (1996) Inhibitors of collagenase but not gelatinase reduce cartilage explant proteolglycan breakdown despite only low levels of matrix metalloproteinase activity. J Clin Pathol: Mol Pathol 49: M331-M339
5. Brown PD, Bloxidge RE, Anderson E and Howell A (1993) Expression of activated gelatinase in human invasive breast carcinoma. Clin Exp Metastasis 11: 183-189
6. Buo L, Meling GI, Karlsrud TS, Johansen HT and Aasen AO (1995) Antigen levels of urokinase plasminogen activator and its receptor at the tumour host interface of colorectal adenocarcinomas are related to aggressiveness. Human Pathol 26: 1133-1138.
7. Cawston TE, Murphy GM, Mercer E, Galloway WA, Hazleman BL and Reynolds JJ (1983) The interaction of purified rabbit bone collagenase with purified rabbit bone metalloproteinase inhibitor. Biochem J 211: 313-318
8. Clavel C, Polette M, Doco M, Binninger I and Birembaut P (1992) Immunolocalisation of matrix metalloproteinases and their tissue inhibitor in human mammary pathology. Bull Cancer 79: 261-270
9. Cocoran ML, Hewitt RE, Kleiner DE and Stetler-Stevenson WG (1996) MMP-2: expression, activation and inhibition. Enzyme Protein 49: 7-19
10. Conway JG, Trexler SJ, Wakefield JA, Marron BE, Emerson DL, Bicketl DM, Deaton DN, Garrison D, Elder M, McElory A, Wilmott N, Dockerty AJP and McGechan GM (1996) Effect of matrix metalloproteinase inhibitors on tumour growth and spontaneous metastasis. Clin Exp Metastasis 14: 115-124
11. Davies B, Miles DW, Happerfield LC, Naylor MS, Bobrow LC, Rubens RD and Balkwill FR (1993) Activity of type IV collagenases in benign and malignant breast tissue. Br J Cancer 76: 1126-1131
12. Duffy MJ, Reilly D, O' Sullivan C, O'Higgins N and Fennelly JJ (1990) Urokinase plasminogen activator and prognosis in breast cancer. Lancet 335: 108-111
13. Gallegos NC, Smales C, Savage FJ, Hembry RM and Boulos PB (1995) The distribution of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal cancer. Surg Oncol 4: 111-119
14. Grondahl-Hansen J, Ralfkiaer E, Kirkeby, Kristensen P, Lund LT and Dano K (1991) Localisation of urokinase type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am J Pathol 138(1): 111-117
15. Hamdy FC, Fadlon EJ, Cottam D, Lawry J, Thurrell W, Silcocks PB, Anderson JB, Williams JL and Rees RC (1994) Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 69: 177-182
16. Heppner KJ, Matrisian LM, Jensen RA and Rodgers WH (1996) Expression of most matrix metalloproteinase family members in breast cancer represents a tumour induced host response. Am J Pathol 149: 273-282
17. Heussen C and Dowdle EB (1980) Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerised substrates. Anal Biochem 102: 196-202
18. Hewitt RE, Leach IH, Powe DG, Clark IM, Cawston TE and Turner DR (1991) Distribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumours. Int J Cancer 49: 666-672
19. Janicke F, Schmitt M and Graeff H (1992) Clinical relevance of the urokinase-type plasminogen activators and their type I inhibitor in breast cancer. Semin Thromb Hemost 17: 303-312
20. Janicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hofler H and Graeff H (1993) Urokinase (uPA) and its inhibitor PAI-1 are strong prognostic factors in node negative breast cancer. Breast Cancer Res Treat 24: 195-208
21. Khokha R, Martin DC and Fata JE (1995) Utilization of transgenic mice in the study of matrix degrading proteinases and their inhibitors. Cancer Metastasis Rev 14: 97-111
22. Knight CG, Willenbrock F and Murphy G (1992) A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS 296: 263-266
23. Kwaan HC (1992) The plasminogen plasmin system in malignancy. Cancer Metastasis Rev 11: 291-311
24. Liabakk NB, Talbot I, Smith RA, Wilkinson K and Balkwill F (1996) Matrix metalloproteinase 2 (MMP-2) and matrix metalloproteinase 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res 56: 190-106
25. Matrisian LM, Wright J, Newell K and Witty JP (1994) Matrix degrading metalloproteinases in tumour progression. Princess Takamatsu Symposia 24: 152-161
26. Murray GI, Duncan ME, O'Neil P, Melvin WT and Fothergill JE (1996) MMP-1 is associated with poor prognosis in colorectal cancer. Nat Med 2: 461-462
27. Parsons SL, Watson SA, Collins HM, Griffin NR, Clarke PA and Steele RJC (1998) Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy. Br J Cancer 78: 1495-1502
28. Polette M, Clavel C, Cockett M, Girod de-Bentzmann S, Murphy G and Birembaut P (1993) Detection and localisation of mRNAs encoding matrix metalloproteinases and their tissue inhibitors in human breast pathology. Invasion Metastasis 13: 31-37
29. Pyke C, Kristensen P, Ralfiaer E, Grondahl-Hansen J, Eriksen J and Dano K (1991) Urokinase-type plasminogen activator is expressed in stromal cells at invasive foci in human colon adenocarcinomas. Am J Pathol 138: 1059-1067
30. Remacle AG, Noel A, Duggan C, McDermott E, O'Higgins N, Foidart JM and Duffy MJ (1998) Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. Br J Cancer 77: 926-931
31. Schmitt M, Goretzki L, Janìcke F, Calvette J, Eulitz M, Kbayashi H, Chucholowski N and Graeff H (1991) Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer. Biomed Biochim Acta 50: 731-741
32. Seftor REB (1994) Electrophoretic analysis of proteins associated with tumour cell invasion. Electrophoresis 15: 454-462
33. Stonelake PS, Jones CE, Neoptolemos JP and Baker PR (1997) Proteinase inhibitors reduce basement membrane degradation by human breast cancer cell lines. Br J Cancer 75: 951-959
34. Taraboletti G, Garofalo A, Belotti D, Drudis T, Borsotti P, Seanziani E, Brown PD and Giavazzi R (1995) Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 87: 293-298
35. Testa JE and Quigley JP (1990) The role of urokinase type plasminogen activator in aggressive tumour cell behaviour. Cancer Metastasis Rev 9: 353-367
36. Torii A, Kodera Y, Uesaka K, Hirai T, Yasui K, Morimoto T, Yamamura Y, Kato T, Hayakawa T, Fujimoto N and Kito T (1997) Plasma concentration of matrix metalloproteinase 9 in gastric cancer. Br J Surg 84: 133-136
37. Yu AE, Hewitt RE, Connor EW and Stetler Stevenson WG (1997) Matrix metalloproteinases: novel targets for directed cancer therapy. Drugs Ageing 11: 229-244